New treatment paradigm for prostate cancer: Abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist

BJU International

Volumn 110, Issue 4, 2012, Pages 499-504

  Garnick, Marc B ^a   Mottet, Nicolas ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Clinique Mutualiste   (France)

Author keywords

abarelix; gonadotrophin releasing hormone antagonists; luteinizing hormone releasing hormone agonists; prostate cancer; testosterone

Indexed keywords

ABARELIX; FOLLITROPIN; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; LUTEINIZING HORMONE; TESTOSTERONE;

ADULT; ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTHRALGIA; ARTICLE; BACKACHE; CANCER HORMONE THERAPY; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; HOT FLUSH; HUMAN; INSOMNIA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; UNITED STATES; URINARY FREQUENCY; WEAKNESS; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GOSERELIN; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE; UNITED STATES;

EID: 84857576096     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10708.x     Document Type: Article

References (10)

1. Mottet N, Bellmunt J, Bolla M, et al,. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59: 572-83
2. Kuhn JM, Billebaud T, Navratil H, et al,. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med 1989; 321: 413-8 (Pubitemid 19211483)
3. McLeod D, Zinner N, Tomera K, et al,. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001; 58: 756-61
4. Trachtenberg J, Gittleman M, Steidle C, et al,. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002; 167: 1670-4 (Pubitemid 34240698)
5. Tomera K, Gleason D, Gittelman M, et al,. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001; 165: 1585-9 (Pubitemid 32410246)
6. Koch M, Steidle C, Brosman S, et al,. An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists. Urology 2003; 62: 877-82 (Pubitemid 37421235)
7. Eisenberger MA, Blumenstein BA, Crawford ED, et al,. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-42 (Pubitemid 28457865)
8. Ben-Josef E, Yang S-Y, Ji TH, et al,. Hormone refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol 1999; 161: 970-6 (Pubitemid 29422418)
9. Teillac P, Debruyne FMJ, Schulman CC, Jonas U, Selvaggi FP, for the ABACAS 1 Study Group. ABACAS 1: a comparison of the efficacy and safety of abarelix versus goserelin plus bicalutamide in patients with advanced or metastatic prostate cancer. A one year randomized open-label multicentre, Phase III trial. Eur Urol 2001; 39 (Suppl. 5): 78
10. Debruyne F,. GnRH antagonists in the management of prostate cancer. Rev Urol 2004; 6 (Suppl. 7): S25-32